Insmed Incorporated [NASDAQ: INSM] slipped around -1.14 points on Friday, while shares priced at $39.11 at the close of the session, down -2.83%. The company report on March 5, 2021 that Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4).
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to seven new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed’s Compensation Committee and made as a material inducement to each employee’s entry into employment with the Company.
In connection with the commencement of their employment, the employees received options on March 1, 2021 to purchase an aggregate 27,770 shares of Insmed common stock at an exercise price of $37.73 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.
Insmed Incorporated stock is now 17.48% up from its year-to-date (YTD) trading value. INSM Stock saw the intraday high of $40.26 and lowest of $39.01 per share. The company’s 52-week high price is 45.44, which means current price is +19.57% above from all time high which was touched on 02/09/21.
Compared to the average trading volume of 926.83K shares, INSM reached a trading volume of 3316245 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Insmed Incorporated [INSM]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for INSM shares is $53.56 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on INSM stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Berenberg have made an estimate for Insmed Incorporated shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 17, 2020. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on October 12, 2020, representing the official price target for Insmed Incorporated stock. Previously, the target price had yet another raise to $30, while Goldman analysts kept a Buy rating on INSM stock. On April 09, 2019, analysts increased their price target for INSM shares from 43 to 52.
The Average True Range (ATR) for Insmed Incorporated is set at 2.24, with the Price to Sales ratio for INSM stock in the period of the last 12 months amounting to 25.23. The Price to Book ratio for the last quarter was 14.49, with the Price to Cash per share for the same quarter was set at 5.02.
How has INSM stock performed recently?
Insmed Incorporated [INSM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.57. With this latest performance, INSM shares dropped by -6.77% in over the last four-week period, additionally plugging by 35.99% over the last 6 months – not to mention a rise of 108.09% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for INSM stock in for the last two-week period is set at 49.64, with the RSI for the last a single of trading hit 49.87, and the three-weeks RSI is set at 50.00 for Insmed Incorporated [INSM]. The present Moving Average for the last 50 days of trading for this stock 38.80, while it was recorded at 39.35 for the last single week of trading, and 33.51 for the last 200 days.
Insmed Incorporated [INSM]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Insmed Incorporated [INSM] shares currently have an operating margin of -161.32 and a Gross Margin at +72.71. Insmed Incorporated’s Net Margin is presently recorded at -178.87.
Return on Total Capital for INSM is now -39.60, given the latest momentum, and Return on Invested Capital for the company is -44.74. Return on Equity for this stock declined to -109.42, with Return on Assets sitting at -38.23. When it comes to the capital structure of this company, Insmed Incorporated [INSM] has a Total Debt to Total Equity ratio set at 146.74. Additionally, INSM Total Debt to Total Capital is recorded at 59.47, with Total Debt to Total Assets ending up at 50.85. Long-Term Debt to Equity for the company is recorded at 142.19, with the Long-Term Debt to Total Capital now at 57.63.
Reflecting on the efficiency of the workforce at the company, Insmed Incorporated [INSM] managed to generate an average of -$564,472 per employee. Receivables Turnover for the company is 9.19 with a Total Asset Turnover recorded at a value of 0.21.Insmed Incorporated’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.80 and a Current Ratio set at 5.20.
Earnings analysis for Insmed Incorporated [INSM]
With the latest financial reports released by the company, Insmed Incorporated posted -0.74/share EPS, while the average EPS was predicted by analysts to be reported at -0.71/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -4.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for INSM.
Insider trade positions for Insmed Incorporated [INSM]
There are presently around $4,238 million, in the hands of institutional investors. The top three institutional holders of INSM stocks are: FMR LLC with ownership of 12,088,544, which is approximately -20.586% of the company’s market cap and around 1.00% of the total institutional ownership; PRICE T ROWE ASSOCIATES INC /MD/, holding 9,652,304 shares of the stock with an approximate value of $377.5 million in INSM stocks shares; and VANGUARD GROUP INC, currently with $366.19 million in INSM stock with ownership of nearly 2.163% of the company’s market capitalization.
Positions in Insmed Incorporated stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 94 institutional holders increased their position in Insmed Incorporated [NASDAQ:INSM] by around 10,811,978 shares. Additionally, 105 investors decreased positions by around 10,693,169 shares, while 32 investors held positions by with 86,866,247 shares. The mentioned changes placed institutional holdings at 108,371,394 shares, according to the latest SEC report filing. INSM stock had 33 new institutional investments in for a total of 3,914,267 shares, while 24 institutional investors sold positions of 1,418,818 shares during the same period.